Study S000573

A Phase 1, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics, Safety, and Tolerability of AMG 133 in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment

ClinicalTrials.gov record

Registration

Registration: NCT07429045
Study type: INTERVENTIONAL
Allocation: NON_RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 44
Start: 2025-03-11
Primary completion: 2025-11-21
Lead sponsor: Amgen
Conditions: Overweight and Obesity
Interventions: DRUG:AMG 133
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Maximum Observed Concentration (Cmax) of AMG 133 [Up to Day 120]
Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120]
AUC From Time 0 Extrapolated to Infinity (AUCinf) of AMG 133 [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.